Solution simplifies complex path to Rx fulfillment

CHICAGO--(BUSINESS WIRE)-- Allscripts Healthcare Solutions (NASDAQ:MDRX) has unveiled a unique new software solution for specialty medication management, delivered by Veradigm™, its business unit focused on payer and life sciences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200304005064/en/

Veradigm’s AccelRx™ is designed to simplify meeting the requirements needed to dispense the increasing number of specialty medications being prescribed. AccelRx leverages broad industry partnerships built over decades of e-prescribing and prior authorization to deliver a user-friendly solution that is helping providers spend less time on phone calls and managing faxes while driving higher patient medication adherence.

Despite representing only 3% of all prescriptions written in the U.S., in 2020, specialty medications are expected to account for up to 50% of the total spend on prescription medications. For a specialty medication prescription to be filled, it must pass through a broad cross-section of healthcare stakeholders, including payers, specialty pharmacies and specialty Rx hubs. The result can be extended patient wait times.

“AccelRx is another example of Veradigm spanning the healthcare ecosystem to find mutually beneficial ways for key stakeholders to work together and to improve patient care,” said Tom Langan, CEO of Veradigm. “By delivering a solution that can automate and simplify the complex series of reviews required to fill a specialty prescription, we believe we can help a broad group of healthcare providers to reduce the time it takes to get these medications to patients.”

Combining one of healthcare’s largest prescriber bases with broad industry partnerships built over decades of e-prescribing and prior authorization leadership, Veradigm AccelRx delivers a solution designed to streamline specialty medication fulfillment and reduce patient wait times.

“There is a growing number of patients affected by the extended delays in receiving their prescribed specialty medications, and it’s a challenge for many segments of the healthcare market including patients and providers,” said Paul Black, Allscripts Chief Executive Officer. “That’s why it is so important to be part of the solution to address this growing need.”

As the impact of specialty medications on healthcare in the U.S. continues to grow, so does the number of patients and providers who can benefit from the value AccelRx provides. As a result, Veradigm is actively engaged in developing ongoing partnerships with key healthcare industry stakeholders to continue expanding the scope of sophistication of the AccelRx solution throughout 2020 and beyond. For more information, visit www.veradigm.com/accelrx.

About Veradigm™

Veradigm is an integrated data systems and services company that combines data-driven clinical insights with actionable tools to help healthcare stakeholders improve the quality, efficiency, and value of healthcare delivery— including biopharma, health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. This is how we are transforming health, insightfully. To learn more, visit www.veradigmhealth.com.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

© 2020 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005064/en/

For more information contact:

Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com

Source: Allscripts